Stem cells for cell replacement therapy: A therapeutic strategy for HD?

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1446-1454

  Rosser, Anne ^a   Svendsen, Clive N ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cell therapy; Fetal cells; Graft; Huntington's; Neural transplant; Stem cells

Indexed keywords

ANIMAL; BIOLOGICAL THERAPY; HUMAN; HUNTINGTON DISEASE; PHYSIOLOGY; PROCEDURES; STEM CELL;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; HUNTINGTON DISEASE; STEM CELLS;

EID: 84907932420     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26026     Document Type: Article

References (59)

1. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 2012;27:1083-1091.
2. Evans S, Douglas I, Rawlins M, Wexler N, Tabrizi S, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 2013;84:1156-1160.
3. Mestre T, Ferreira J. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Disord 2012;18:316-320.
4. Lee J, Hwang YJ, Kim KY, Kowall NW, Ryu H. Epigenetic mechanisms of neurodegeneration in Huntington's disease. Neurotherapeutics 2013;10:664-676.
5. Mantha N, Das K, Das N. RNAi-based therapies for Huntington's disease: delivery challenges and opportunities. Ther Deliv 2012;3:1061-1076.
6. Dunnett SB, Rosser AE. Cell-based treatments for Huntington's disease. Int Rev Neurobiol 2011;98:483-508.
7. Vonsattel JP, Myer R, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol. 1985;44:559-577.
8. Oberheim N, Goldman S, Nedergaard M. Heterogeneity of astrocytic form and function. Methods Mol Biol 2012;814:23-45.
9. Wyse R, Dunbar G, Rossignol J. Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int J Mol Sci 2014;15:1719-1745.
10. Petit G, Olsson T, Brundin P. The future of cell therapies and brain repair: Parkinson's disease leads the way. Neuropathol Appl Neurobiol 2014;40:60-70.
11. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
12. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
13. Lindvall O. Developing dopaminergic cell therapy for Parkinson's disease: give up or move forward? Mov Disord 2013;28:268-273.
14. Nicoleau C, Viegas P, Peschanski M, Perrier AL. Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges. Neurotherapeutics 2011;8:562-576.
15. Shelley B, Gowing G, Svendsen CN. A cGMP-applicable expansion method for aggregates of human neural stem and progenitor cells derived from pluripotent stem cells or fetal brain tissue. J Vis Exp 2014;88.
16. Tabrizi S, Scahill R, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
17. Dunnett SB, Rosser AE. Challenges for taking primary and stem cells into clinical neurotransplantation trials for neurodegenerative disease. Neurobiol Dis 2014;61:79-89.
18. Bachoud-Levi A, Remy P, Nguyen J, et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000;356:1975-1979.
19. Gaura V, Bachoud-Lévi A, Ribeiro M, et al. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 2004;127:65-72.
20. Rosser AE, Bachoud-Lévi AC. Clinical trials of neural transplantation in Huntington's disease. Prog Brain Res 2012;200:345-371.
21. Bachoud-Lévi A, Gaura V, Brugières P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5:303-309.
22. Freeman T, Cicchetti F, Bachoud-Lévi A, Dunnett SB. Technical factors that influence neural transplant safety in Huntington's disease. Exp Neurol 2011;227:1-9.
23. Muldoon L, Alvarez J, Begley D, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 2013;33:13-21.
24. Krystkowiak P, Gaura V, Labalette M, et al. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS One 2007;2:e166.
25. Kokaia Z, Lindvall O. Stem cell repair of striatal ischemia. Prog Brain Res 2012;201:35-53.
26. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010;90:905-981.
27. Shin E, Garcia J, Winkler C, Björklund A, Carta M. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol Dis 2012;47:393-406.
28. Viegas P, Nicoleau C, Perrier A. Derivation of striatal neurons from human stem cells. Prog Brain Res 2012;200:373-404.
29. Precious SV, Rosser AE. Producing striatal phenotypes for transplantation in Huntington's disease. Exp Biol Med 2012;237:343-351.
30. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 2008;105:16707-16712.
31. Carri A, Onorati M, Lelos M, et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 2013;140:301-312.
32. Ma L, Hu B, Liu Y, et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 2012;10:455-464.
33. Gao P, Sultan K, Zhang X, Shi S. Lineage-dependent circuit assembly in the neocortex. Development 2013;140:2645-2655.
34. Taylor C, Bolton E, Bradley J. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 2011;366:2312-2322.
35. Wright L, Phillips M, Pinilla I, Hei D, Gamm DM. Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale. Exp Eye Res 2014;S0014-4835:00345-X.
36. Olson S, Pollock K, Kambal A, et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 2012;45:87-98.
37. Olson S, Kambal A, Pollock K, et al. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin. Mol Cell Neurosci 2012;49:271-281.
38. 3H]thymidine autoradiographic analysis of the time of neuron origin in the rhesus monkey Neuroscience 1979;4:767-778.
39. Stiles J, Jernigan T. The basics of brain development. Neuropsychol Rev 2010;204:327-348.
40. Frisen J, Johnansson C, Torok C, Risling M, Lendahl U. Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. J Cell Biol 1995;131:453-464.
41. Cajal SR. Recollections of My Life. 1989. The MIT Press, England, p. 638.
42. Luskin M. Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron 1993;11:173-189.
43. Berrais A, Chmielinicki E, Lerner K, Roh D, Goldman S. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci 2001;21:6718-6731.
44. Sanai N, Nguyen T, Ihrie R, et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature 2011;478:382-386.
45. Li Y, Mu Y, Gage FH. Development of neural circuits in the adult hippocampus. Curr Top Dev Biol 2009;87:149-174.
46. Rakic P. Limits of neurogenesis in primates. Science 1985;227:1054-1056.
47. Cho S, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 2007;117:2889-2902.
48. Chen J, Magavi S, Macklis J. Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice. Proc Natl Acad Sci U S A 2004;101:16357-16362.
49. Ernst A, Alkass K, Bernard S, et al. Neurogenesis in the striatum of the adult human brain. Cell 2014;156:1072-1083.
50. Dunnett SB. Functional repair of striatal systems by neural transplants: evidence for circuit reconstruction. Behav Brain Res 1995;66:133-142.
51. Dobrossy M, Dunnett SB. The effects of lateralized training on spontaneous forelimb preference, lesion deficits, and graft-mediated functional recovery after unilateral striatal lesions in rats. Exp Neurol 2006;199:373-383.
52. Hurelbrink C, Armstrong R, Dunnett S, Rosser A, Barker, R. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci 2002;15:1255-1266.
53. Cicchetti F, Saporta S, Hauser R, et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 2009;106:12483-12488.
54. Ma Y, Feigin A, Fukuda M, et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Ann Neurol 2002;52:628-634.
55. Hagell P, Cenci M. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res Bull 2005;68:4-15.
56. Li J, Englund E, Widner H, et al. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010;25:1091-1096.
57. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012;11:264-278.
58. McBride J, Behrstock S, Chen E, et al. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol 2004;475:211-219.
59. Ebert E, Barber A, Heins B, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 2010;224:155-162.